ZIOPHARM Oncology Inc (NASDAQ:ZIOP) CEO Laurence James Neil Cooper purchased 6,440 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the completion of the transaction, the chief executive officer now directly owns 1,083,731 shares in the company, valued at approximately $5,071,861.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

ZIOPHARM Oncology Inc (ZIOP) traded down $0.25 during mid-day trading on Friday, hitting $4.30. 3,276,056 shares of the stock traded hands, compared to its average volume of 1,335,313. ZIOPHARM Oncology Inc has a twelve month low of $4.16 and a twelve month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. During the same period in the previous year, the company earned ($0.11) earnings per share. The company’s revenue was up .0% compared to the same quarter last year. research analysts predict that ZIOPHARM Oncology Inc will post -0.54 earnings per share for the current year.

WARNING: “ZIOPHARM Oncology Inc (ZIOP) CEO Laurence James Neil Cooper Purchases 6,440 Shares of Stock” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/ziopharm-oncology-inc-ziop-ceo-laurence-james-neil-cooper-purchases-6440-shares-of-stock/1694212.html.

Several equities research analysts have weighed in on the company. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Friday. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. ZIOPHARM Oncology has a consensus rating of “Hold” and an average target price of $12.58.

Hedge funds have recently bought and sold shares of the company. Amalgamated Bank boosted its stake in shares of ZIOPHARM Oncology by 12.9% during the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,924 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of ZIOPHARM Oncology by 50.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 6,000 shares in the last quarter. BB&T Securities LLC purchased a new stake in shares of ZIOPHARM Oncology during the 2nd quarter worth about $112,000. Adell Harriman & Carpenter Inc. purchased a new stake in shares of ZIOPHARM Oncology during the 3rd quarter worth about $141,000. Finally, Principal Financial Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 7.5% during the 2nd quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 1,673 shares in the last quarter. 41.86% of the stock is currently owned by institutional investors and hedge funds.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.